People · Operator

David S. Washburn

Named in public records as an officer, director or promoter · active 2011–2023 · Software / Tech, Biotechnology

3
Companies
6
Filings
$33.7M
Combined raised · real
Serial
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Acuitive Technologies, Inc.Software / TechSeries A$22.5M$90.3M2021
Pipeline Biomedical, Inc.BiotechnologySeries A$8.0M$289.2M2011
Pipeline Biomedical Holdings, Inc.BiotechnologySeed$3.2M$142.1M2012
Operator network

David S. Washburn at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Alex S. Khowaylo · 1 companies · 1 sharedAlex S. KhowayloGary S. Fischetti · 1 companies · 1 sharedGary S. FischettiJames S. Maylayter · 1 companies · 1 sharedJames S. MaylayterMichael S. McCarthy · 1 companies · 1 sharedMichael S. McCart…Vincent S. Forlenza · 1 companies · 1 sharedVincent S. Forlen…Alex Khowaylo · 3 companies · 3 sharedAlex KhowayloMichael P. McCarthy · 3 companies · 3 sharedMichael P. McCart…Larry P. Feinberg · 2 companies · 2 sharedLarry P. FeinbergRobert C. Cohen · 2 companies · 2 sharedRobert C. CohenAcuitive Technologies, Inc. · $22.5M raisedAcuitive Technologies…Pipeline Biomedical, Inc. · $8.0M raisedPipeline Biomedical, …Pipeline Biomedical Holdings, Inc. · $3.2M raisedPipeline Biomedical H…David S. WashburnDW
David S. Washburn Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside David S. Washburn on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Michael P. McCarthy33
Alex Khowaylo33
Larry P. Feinberg22
Robert C. Cohen22
Alex S. Khowaylo11
Michael S. McCarthy11
Gary S. Fischetti11
James S. Maylayter11
Vincent S. Forlenza11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.